Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
ESPERION THERAPEUTICS INC Create: Alert

All | News | Filings
Date FiledTypeDescription
02/11/2004 8-K Quarterly results
01/23/2004 8-K Quarterly results
Docs: "ESPERION REPORTS FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED DECEMBER 31, 2003"
12/23/2003 8-K Other events, Financial statements and exhibits
Docs: "Agreement and Plan of Merger, by and among Pfizer Inc., Enzo",
"Amendment No. 3, to the Rights Agreement, between Esperion Therapeutics, Inc",
"Amendment, to Collaboration and License Agreement, between Esperion"
10/20/2003 8-K Quarterly results
Docs: "ESPERION REPORTS FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED SEPTEMBER 30, 2003"
07/29/2003 8-K Other events, Financial statements and exhibits
Docs: "EXHIBIT NO. EXHIBIT DESCRIPTION",
"Amendment No. 2 to Rights Agreement, between Esperion Therapeutics, Inc. and StockTrans, Inc., as Rights Agent",
"Voting and Transfer Restriction Agreement by and among Esperion Therapeutics, Inc., Scott Sacane, Durus Capital Management, LLC and Durus Capital Management (NA), LLC"
07/16/2003 8-K Financial statements and exhibits, Regulation FD Disclosure
04/17/2003 8-K Financial statements and exhibits, Regulation FD Disclosure
Docs: "ESPERION REPORTS FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2003"
11/26/2002 8-K Other events, Financial statements and exhibits
Docs: "EXHIBIT NO. EXHIBIT DESCRIPTION",
"Amendment No. 1 to Rights Agreement, between Esperion Therapeutics, Inc. and StockTrans, Inc., as Rights Agent"
04/23/2002 8-K Changes in registrant's certifying accountant, Other events, Financial statements and exhibits
Docs: "EXHIBIT NO. EXHIBIT DESCRIPTION",
"Certificate of Designations, Preferences, Related Rights, Qualifications, Limitations and Restrictions of Series A Junior Participating Preferred Shares",
"Rights Agreement, between Esperion Therapeutics, Inc. and StockTrans, Inc., as Rights Agent Exhibit 16 Letter from Arthur Andersen LLP to the Securities and Exchange Commission",
"FROM ARTHUR ANDERSEN LLP",
"President and CEO Timothy M. Mayleben JFCI"
11/22/2000 8-K/A Financial statements and exhibits
Docs: "ESCROW AND PARTICIPATION AGREEMENT",
"Consent of Goldenberg Rosenthal, LLP",
"Financial statements for the year ended December 31, 1999 and for the period from October 2, 1998 (inception) to December 31, 1998 @ Confidential Treatment Requested (1) Previously filed on October 6, 2000 on Form 8-K. (2) Previously filed on October 6, 2000 on Form 8-K and refiled herewith. *The schedules, including disclosure schedules, and similar attachments to the Agreement and Plan of Merger and Reorganization have been omitted. The disclosure schedules include exceptions and disclosures made by Talaria Therapeutics, Inc. ("Talaria") in connection with the following: corporate existence and power; government authorization; non-contravention of organizational documents, laws and other obligations; capitalization of Talaria; absence of undisclosed liabilities; title to properties and a..."
10/06/2000 8-K Acquisition or disposition of assets, Financial statements and exhibits
Docs: "AGREEMENT AND PLAN OF",
"Indemnification, Escrow and Participation Agreement by and among Esperion Therapeutics, Inc., the stockholders of Talaria Therapeutics, Inc., Rock Hill Ventures, Inc. and Sills Cummis Radin Tischman Epstein & Gross",
"Non-Competition Agreement by and among Esperion Therapeutics, Inc., Esperion Mergerco, Inc. and certain Talaria Parties",
"Consent of Goldenberg Rosenthal, LLP",
"ESPERION THERAPEUTICS, INC. ANNOUNCES THE ACQUISITION OF TALARIA THERAPEUTICS, INC."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy